Skip to content
GLP-1 Scorecard
Menu
Graded #36

Ro

A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.

Visit RoWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Multi-state
Brand-name
Yes

Line Ro up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value68/100
Dose & formulation86/100
Clinical oversight86/100
Labs & monitoring82/100
Fulfillment84/100
Contract terms80/100

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Well-funded platform

Where it loses points

  • Does not disclose compounded pricing up front
  • Premium positioning

Bottom line — Grade B−

Best for: Patients who want brand-name capability and insurance navigation.

Ranked #36 of 508 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Ro — the realistic shortlist.

The 22 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Ro's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.

← Back to the scorecard